Half a decade of data on the second generation iStent inject has shown a significant reduction in intraocular pressure (IOP) and medication burden in glaucoma patients.
Read More
Glaukos commences trials for its third-generation keratoconus therapy
Glaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus.
Read More
Read More
Aussie study offers new MIGS head-to-head comparison
Australian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no significant difference in intraocular pressure (IOP) outcomes but a potential greater reduction in medication use in one group.
Read More
Read More
Dr Nathan Kerr performs Victorian-first PRESERFLO MicroShunt procedure
Glaucoma surgeon Dr Nathan Kerr has performed Victoria’s first procedure with the PRESERFLO MicroShunt, first approved by the Therapeutic Goods Administration (TGA) in mid-2021.
Read More
Read More
Glaukos trials eyelid cream to treat presbyopia and dry eye
Glaukos has commenced Phase 2 trials of two investigational cream-based drug candidates that are applied to the eyelids to treat dry eye and presbyopia.
Read More
Read More
Ivantis to pay Glaukos US$60 million in MIGS patent settlement
MIGS device manufacturer Glaukos has reached an agreement with Ivantis over a patent infringement lawsuit regarding the latter’s Hydrus Microstent for glaucoma.
Read More
Read More
Glaukos pens new deal for Preserflo MicroShunt
Glaukos has signed a new license agreement with Santen Pharmaceutical for the Preserflo MicroShunt, obtaining exclusive rights for the therapy in Australia, New Zealand and other territories.
Read More
Read More
Glaukos introduces the iprism SX
Glaukos has unveiled a new single-use surgical gonioscopy lens that is said to provide exceptional clarity with expanded views of angle structures.
Read More
Read More
Sector embraces government approval of standalone MIGS
From this month, surgeons can perform standalone minimally invasive glaucoma surgery (MIGS) under Medicare, seeing Australia become the first major developed economy to universally approve the procedure in both public and private settings.
Read More
Read More